Back

A tumorigenesis threshold for endogenous Myc revealed by dosage-compensation for Myc haploinsufficiency in the absence of p53.

Bao, X.; Abdullaev, Z.; Subhendu, D. K.; Zgonc, V.; Ylaya, K.; Chung, J.-Y.; Pittaluga, S.; Hewitt, S. M.; Sedivy, J. M.; Pack, S.; Mackem, S.; Levens, D.

2025-07-31 cancer biology
10.1101/2025.07.28.667174 bioRxiv
Show abstract

The MYC proto-oncogene is crucial for neoplasia in most tumors. Overexpressed, oncogenic MYC amplifies the flux through most major processes but does not specify a unique carcinogenic pathway. This "amplifier" model suggests that MYC must exceed an expression threshold to become oncogenic. We designed a genetic test of this model, using the mouse Trp53 null mutant (p53KO) as a highly robust tumor generator to examine the effect of a modest change in the endogenous Myc level (Myc+/-). Strikingly, tumor-free survival is greatly extended in p53KO mice with haploid Myc gene-dosage, yet in the tumors that do develop (mainly hemangiosarcomas and thymic lymphomas), their Myc deficit has been invariably compensated either by increasing Myc genomic dosage (hemangiosarcomas) or expression (lymphomas). Furthermore, acutely halving the endogenous Myc gene-dosage in established tumor allografts curtails growth rates. These results indicate that even an incremental reduction of MYC activity can be salutary in cancer and that one of the major tumor suppressor functions of p53 derives from its ability to prevent MYC overexpression. Myc generates acute DNA damage by several mechanisms and accordingly, p53s anti-Myc function may be inextricably linked to its role in genome integrity surveillance.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.